Recent Updates
Recently added Catalysts
SYK Positive Sentiment

Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal

Key Takeaway: Stryker has received FDA 510(k) clearance for its Sonopet 3, an advanced ultrasonic tissue removal platform. Designed with surgeon collaboration, it enhances power, precision, and workflow efficiency. Key features include RISE for integrated surgical experiences and Pulse Control for better tissue resection. Clinical use is expected to start in October 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sonopet 3 offers enhanced power and precision for tissue removal.
  • Developed with direct input from surgeons, ensuring user needs are met.
  • New technologies like RISE and Pulse Control improve surgical workflows.

Full Press Release Details

• Stryker has received FDA 510(k) clearance for Sonopet ® 3, the latest evolution of its ultrasonic bone and soft tissue removal platform.
• Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
• Customers gain access to advanced technologies including RISE and Pulse Control, supporting streamlined workflows and integration across surgical settings.
PORTAGE, Mich., Oct. 14, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. Food and Drug Administration.
Developed with input from hundreds of surgeons, Sonopet 3 is designed to deliver enhanced power, precision and versatility in a single platform for tissue removal. Surgeon collaboration directly shaped the new platform, informing key improvements in performance, workflow efficiency and clinical priorities.
"At Stryker, innovation begins with listening to our customers," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. "Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we're elevating the standard in neurosurgery. They told us they wanted more power, improved ergonomics and enhanced integration, helping them perform with confidence in demanding surgical environments."
In addition to performance enhancements, Sonopet 3 provides access to the platform's latest technologies, including RISE, a Reimagined Integrated Surgical Experience for a connected surgical workflow, and Pulse Control, which provides an added ability to regulate the resection of hard and soft tissues. Together, these advancements help support integration across surgical workflows.
The first clinical cases using Sonopet 3 are expected to begin in October, with a full commercial launch anticipated later this fall.
About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Media contact Stryker Jenny Braga Senior Director, External Affairs [email protected]

Frequently Asked Questions

What is Sonopet 3?

Sonopet 3 is Stryker's latest ultrasonic bone and soft tissue removal platform.

When did Sonopet 3 receive FDA clearance?

Sonopet 3 received FDA 510(k) clearance on October 14, 2026.

What technologies are included in Sonopet 3?

Sonopet 3 features RISE for integrated workflows and Pulse Control for tissue resection.

Who contributed to the development of Sonopet 3?

The platform was developed in collaboration with hundreds of surgeons.

When will clinical cases using Sonopet 3 begin?

Clinical cases using Sonopet 3 are expected to start in October 2026.

Last updated: Oct 14, 2026